Comparative Study of the Efficacy of Newer Antioxitands Lycopene and Oxitard in the Treatment of Oral Submucous Fibrosis

Santosh R Patil, Nidhi Yadav, Ibrahim A Al-Zoubi, G Maragathavalli, Mohammed G. Sghaireen, Ravi Kumar Gudipaneni, Mohammad Khursheed Alam

Abstract


Objective: To compare the efficacy of oxitard and lycopene in the management of Oral Submucous Fibrosis (OSMF). Material and Methods: 120 subjects with clinic-pathologically diagnosed OSMF were included in the study and divided equally in 2 groups, Group A (oxitard) and Group B (lycopene). Group A was administered 2 oxitard capsules twice daily and Group B was given 8 mg lycopene in 2 divided doses of 4 mg for 3 months. Gingival index and plaque index were documented for all patients and compared. Evaluation for different clinical parameters was done at regular intervals and data was analyzed using the Student’s paired t test and Chi-square test. P-value <0.001 was considered to be statistically significant. Results: Clinical improvements in mouth opening and tongue protrusion was significant in Group A (p<0.001). Subjective symptoms of pain associated with the lesion (p=0.0001), difficulty in swallowing (p=0.0004) and speech (p=0.0002) significantly improved in the Group A. However, there was no significant improvement in burning sensation (p>0.001) among the 2 groups. Although the mean gingival index and plaque index in group A was reduced but it was found to be not statistically significant. Conclusion: Oxitard capsules can bring about significant clinical improvements in the symptoms like mouth opening, tongue protrusion, difficulty in swallowing and speech and pain associated with the lesion when compared to lycopene, thereby improving the quality of life of the affected individuals.


Keywords


Oral Submucous Fibrosis; Antioxidants; Burning Mouth Syndrome.

Full Text:

PDF

References


Patil S, Maheshwari S. Proposed new grading of oral submucous fibrosis based on cheek flexibility. J Clin Exp Dent 2014; 6(3):e255-e258. doi: 10.4317/jced.51378.

Patil S, Al-Zarea BK, Maheshwari S, Sahu R. Comparative evaluation of natural antioxidants spirulina and aloe vera for the treatment of oral submucous fibrosis. J Oral Biol Craniofac Res 2015; 5(1):11-5. doi: 10.1016/j.jobcr.2014.12.005.

Patil S, Halgatti V, Maheshwari S, Santosh BS. Comparative study of the efficacy of herbal antioxdants oxitard and aloe vera in the treatment of oral submucous fibrosis. J Clin Exp Dent 2014; 6(3):e265-e270. doi: 10.4317/jced.51424.

Patil S, Maheshwari S. Efficacy of pentoxifylline in the management of oral submucous fibrosis. J Orofac Sci 2014; 6:94-8. doi: 10.4103/0975-8844.143048.

Zwiri AMA, Patil S, Yadav N. Comparative evaluation of newer drugs pentoxifylline and spirulina in the management of OSMF. Int J Pharmacol Toxicol 2015; 5(3):141-5.

Singh BP, Mittal N, Sharma V, Palani. Evaluation of role of oxitard capsules in the treatment of oral submucous fibrosis. The Antiseptic 2009; 106:503-7.

Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(2):207-13. doi: 10.1016/j.tripleo.2006.07.011.

Karemore TV, Motwani M. Evaluation of the effect of newer antioxidant lycopene in the treatment of oral submucous fibrosis. Indian J Dent Res 2012; 23(4):524-8. doi: 10.4103/0970-9290.104964.

Loe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963; 21(6):533-51. doi: 10.3109/00016356309011240.

Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condtion. Acta Odontol Scand 1964; 22(1):121-35. doi: 10.3109/00016356408993968.

Ramadass T, Manokaran G, Pushpala SM, Narayanan N, Kulkarni GN. Oral submucous fibrosis - New dimensions in surgery. Indian J Otolaryngol Head Neck Surg 2005; 57(2):99-102. doi: 10.1007/BF02907659.

Cjambras RG, Jaques DA, Mohoney WE. Tongue flaps for intraoral reconstruction. Am J Surg 1969; 118(5):783-6. doi: 10.1016/0002-9610(69)90229-3.

Canniff JP, Harvey W. The aetiology of oral submucous fibrosis: The stimulation of collagen synthesis by extracts of areca nut. Int J Oral Surg 1981; 10(Suppl 1):163-7.

More CB, Das S, Patel H, Adalja C, Kamatchi V, Venkatesh R. Proposed clinical classification for oral submucous fibrosis. Oral Oncol 2012; 48(3):200-2. doi: 10.1016/j.oraloncology.2011.10.011.

Dodani K, Anumala N, Avula H, Reddy K, Varre S, Kalakonda BB et al. Periodontal findings in patients with oral submucous fibrosis and comet assay of affected gingival epithelial cells. J Periodontol 2012; 83(8):1038-47. doi: 10.1902/jop.2011.110352.

Yoithapprabhunath TR, Maheswaran T, Dineshshankar J, Anusushanth A, Sindhuja P, Sitra G. Pathogenesis and therapeutic intervention of oral submucous fibrosis. J Pharm Bioallied Sci 2013; 5(Suppl 1):S85–S88. doi: 10.4103/0975-7406.113303.

Maher R, Aga P, Johnson NW, Sankaranarayanan R, Warnakulasuriya S. Evaluation of multiple micronutrient supplementation in the management of oral submucous fibrosis in Karachi, Pakistan. Nutr Cancer 1997; 27(1):41-7. doi: 10.1080/01635589709514499.

Borle RM, Borle SR. Management of oral submucous fibrosis: A conservative approach. J Oral Maxillofac Surg 1991; 49(8):788-91. doi: 10.1016/0278-2391(91)90002-4.

Teodoro AJ, Oliveira FL, Martins NB, Maia GA, Martucci RB, Borojevic R. Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. Cancer Cell Int 2012; 12(1):36. doi: 10.1186/1475-2867-12-36.

Palozza P, Catalano A, Simone R, Cittadini A. Lycopene as a guardian of redox signalling. Acta Biochim Pol 2012; 59(1):21-5.




DOI: http://dx.doi.org/10.4034/PBOCI.2018.181.67

PBOCI IS A MEMBER OF CROSSREF AND ALL THE CONTENT OF ITS JOURNALS ARE LINKED BY DOIS THROUGH CROSSREF.